CIK 0001609809
- Non-accelerated filer
- Smaller reporting company
Seres Therapeutics, Inc.
Sign in to watch- Ticker
- MCRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 274326290
- Phone
- +1 617-945-9626
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $795
- in 4 filings, $795 under 10b5-1 plans
Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-15 | Ege David S. | Sale 10b5-1 | −1,090 | $0.94 | $1K | 75,734 |
| 2024-05-15 | Ege David S. | Exercise or conversion · Restricted Stock Units 10b5-1 | −2,968 | 32,657 | ||
| 2024-05-15 | DesRosier Thomas Chief Legal Officer and EVP | Exercise or conversion 10b5-1 | +2,656 | 123,233 | ||
| 2024-05-15 | DesRosier Thomas Chief Legal Officer and EVP | Sale 10b5-1 | −843 | $0.94 | $792 | 122,390 |
| 2024-05-15 | DesRosier Thomas Chief Legal Officer and EVP | Exercise or conversion · Restricted Stock Units 10b5-1 | −2,656 | 29,219 | ||
| 2024-04-04 | Biondi Paul Director | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2024-04-04 | Ausiello Dennis A Director | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2024-04-04 | Fraser Claire Director | Grant or award · Stock Option (right to buy | +60,000 | 60,000 | ||
| 2024-04-04 | Graves Kurt Director | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2024-04-04 | Berenson Stephen Director | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2024-04-04 | Dere Willard H Director | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2024-04-04 | Kender Richard N Director | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2024-03-25 | Thorell Marella | Grant or award · Stock Options (right to buy) | +700,000 | 700,000 | ||
| 2024-02-16 | DesRosier Thomas Chief Legal Officer and EVP | Sale 10b5-1 | −3,939 | $1.08 | $4K | 120,577 |
| 2024-02-16 | Shaff Eric D. CEO and President | Sale 10b5-1 | −11,549 | $1.08 | $12K | 135,321 |
| 2024-02-16 | Henn Matthew R. | Sale 10b5-1 | −4,170 | $1.08 | $5K | 63,436 |
| 2024-02-16 | Young Teresa L. | Sale 10b5-1 | −3,374 | $1.08 | $4K | 15,705 |
| 2024-02-16 | von Moltke Lisa | Sale 10b5-1 | −4,400 | $1.08 | $5K | 16,988 |
| 2024-02-16 | Ege David S. | Sale 10b5-1 | −5,010 | $1.08 | $5K | 73,856 |
| 2024-02-16 | Arkowitz David Chief Financial Officer | Sale 10b5-1 | −3,939 | $1.08 | $4K | 182,442 |
Page 14 of 23 · 458 trades